NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection |
|
|
| Terminated | 2 | 7 | US | Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay | Washington University School of Medicine, Genentech, Inc. | Stage II Melanoma | 11/23 | 11/23 | | |
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors |
|
|
| Recruiting | N/A | 100 | US | | Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS) | Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma | 12/25 | 12/25 | | |